Article
Partnership brings Iterative Scopes’ AI Recruitment technology to One GI® Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Iterative Scopes, a pioneer in precision-medicine technologies for gastroenterology, announced today that it has partnered with One GI®, a gastroenterology management services organization (MSO), to bring its AI Recruitment (AIR) technology to One GI’s clinical research. Initially, One…
Read More
Plans for the round include investing in R&D for its tech platform and hiring across all teams. The news follows the company’s recent move to a new Center City office. Excerpt from the Press Release: Following a $20 million Series B round last year, NeuroFlow just closed a $25 million round of financing to continue…
Read More
Next Generation Senza® HFX iQ™ is the First and Only SCS System that Uses Artificial Intelligence to Optimize and Maintain Pain Relief Using Each Patient’s Response Excerpt from the Press Release: REDWOOD CITY, Calif., Oct. 12, 2022 /PRNewswire/ — Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the…
Read More
– Six-year natural history comparison with maralixibat demonstrates event-free and transplant-free survival in patients with Alagille syndrome (ALGS) – Characterization of four-year growth improvement in Alagille syndrome with maralixibat – New analysis evaluating health-related quality of life impact assessed on caregivers of children with Alagille syndrome – Mirum to host a scientific symposium on the…
Read More
AtomVie Global Radiopharma is the latest company launched by the OICR-supported centre Excerpt from the Press Release: The Centre for Probe Development and Commercialization’s (CPDC) newest spinout company has now launched as AtomVie Global Radiopharma Inc. On August 24, the Hamilton-based radiopharmaceutical company announced it had closed Series A financing with healthcare investment firm Avego…
Read More
FDA Meeting Planned for Q4 to Discuss Regulatory Path Forward Based on Encouraging Results to Date in Ongoing RAMP 201 Trial in LGSOC Results of Part A of RAMP 202 Trial in KRAS G12V-Mutant NSCLC Show VS-6766 ± Defactinib Did Not Meet Criteria to Continue to Expansion Phase RAMP Trials with VS-6766 Combinations in KRAS…
Read More
Eight patients have been treated in the ongoing Phase 1/2 First-in-Human clinical trial with favorable safety and tolerability observed to date Assessments of the initial 3 patients reaching their six-month follow-up showed improvements on validated functional scales and increases in brain white matter and myelin content Encouraging efficacy and safety data support further development of…
Read More
— Immune responses observed in endometrial cancer and glioblastoma models, complementing prior clinical success in glioblastoma and supporting further development of IEC-001 for the treatment of endometrial cancer — — Data further elucidates foundational anti-tumor mechanisms of the company’s immunotherapeutic platform — Excerpt from the Press Release: PHILADELPHIA–(BUSINESS WIRE)–Imvax, Inc., a clinical-stage biotechnology company developing…
Read More
Results showed evidence of clinical activity for cirtuvivint in advanced cancer patients Excerpt from the Press Release: SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) — Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, announced today the presentation of new clinical data for cirtuvivint (SM08502), its…
Read More
Subjects enrolled with biopsy confirmed NASH experienced clinically and statistically significant improvements in liver stiffness as measured by FibroScan, a non-invasive measure of liver fibrosis Subjects with NASH experienced clinically and statistically significant improvements in alanine aminotransferase (ALT), a measure of liver cell inflammation, at both dose levels of AXA1125 Findings demonstrate improvement in hepatic…
Read More